Cervical Cancer Market

 Market Overview:

The 7 major cervical cancer markets reached a value of US$ 405.6 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 583.4 Million by 2034, exhibiting a growth rate (CAGR) of 3.36% during 2024-2034.

The cervical cancer market has been comprehensively analyzed in IMARC's new report titled "Cervical Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cervical cancer refers to a type of cancer that originates in the cells of the cervix, which is the lower, narrow end of the uterus that connects to the upper vaginal opening. It primarily affects women, but in rare cases, it can also occur in individuals with a cervix who were assigned male at birth. Cervical cancer may not cause noticeable symptoms in its early stages. However, as the disease progresses, various indications associated with the ailment may include abnormal vaginal bleeding (post menopause, between periods, or after sexual intercourse), unusual vaginal discharge, pelvic pain, pain during urination, fatigue, unexplained weight loss, etc. The diagnosis of cervical cancer typically involves a combination of screening tests, clinical examinations, and diagnostic procedures. Numerous screening tests, such as pap smears or human papillomavirus (HPV) testing, are used to detect cellular anomalies or the presence of high-risk HPV types. If abnormalities are found, further diagnostic procedures like colposcopy (visual examination of the cervix), biopsy (sample collection for laboratory analysis), or imaging tests may be performed to confirm the diagnosis of cervical cancer or determine its extent and stage.

The escalating cases of human papillomavirus (HPV) infection, which can cause changes in the cellular structure and DNA, thereby leading to the development of precancerous lesions, are primarily driving the cervical cancer market. Additionally, the rising prevalence of various associated risk factors, including engaging in sexual activity at an early age, weakened immune system, long-term use of oral contraceptives, multiple sexual partners, a history of sexually transmitted infections (STIs), etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of immune checkpoint inhibitors, such as pembrolizumab and nivolumab, which block certain proteins in cancer cells, allowing the immune system to recognize and destroy cancer cells more effectively, is further bolstering the market growth. Apart from this, the inflating application of adaptive radiation therapy, since it allows for precise radiation delivery, thereby minimizing damage to healthy tissue while maximizing tumor control, is acting as another significant growth-inducing factor. Additionally, the shifting preferences from conventional pap smears towards liquid-based cytology on account of its several associated benefits, including better cell preservation and reduced specimen variability, are expected to drive the cervical cancer market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the cervical cancer market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for cervical cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cervical cancer market in any manner.

Recent Developments:

• In April 2024, Pfizer Inc. and Genmab A/S announced that the U.S. Food and Drug Administration (FDA) had approved the supplemental Biologics License Application (sBLA) for TIVDAK (tisotumab vedotin-tftv) for the treatment of recurrent or metastatic cervical cancer with disease progression during or after chemotherapy.
• In November 2023, TheraVectys announced that the U.S. FDA had completed its safety review of the Investigational New Drug (IND) application and concluded that TheraVectys’ proposed clinical study may proceed to evaluate the oncotherapeutic vaccine Lenti-HPV-07 for the treatment of human papillomavirus (HPV)-induced cancers, including oropharyngeal and cervical cancers.

Key Highlights:

• Cervical cancer is the fourth most frequent malignancy among women globally.
• Countries with low or middle incomes have the greatest incidence and mortality rates for cervical cancer.
• The HPV is the major cause of cervical cancer, with a persistent HPV infection accounting for more than 99% of cases.
• HIV-positive women are six times more likely to acquire cervical cancer than those without the virus.
• Cervical cancer incidence and mortality are highest in Sub-Saharan Africa, Central America, and Southeast Asia.

Drugs:

TIVDAK (tisotumab vedotin-tftv) is an antibody-drug conjugate (ADC) made up of Genmab's human monoclonal antibody directed to tissue factor (TF) and Pfizer's ADC technology, which uses a protease-cleavable linker to covalently attach the microtubule-disrupting agent monomethyl auristatin E (MMAE) to the antibody. Nonclinical findings imply that tisotumab vedotin-tftv's anticancer action is due to the ADC binding to TF-expressing cancer cells, followed by internalization of the ADC-TF complex and release of MMAE via proteolytic cleavage.

Cemiplimab is a completely human monoclonal antibody that targets the immunological checkpoint receptor PD-1 on T cells, developed utilizing Regeneron's unique VelocImmune technology. Cemiplimab's binding to PD-1 has been proven to prevent cancer cells from exploiting the PD-1 pathway to decrease T-cell activation.

LN-145 is a tumor-infiltrating lymphocyte (TIL) treatment technique that the FDA has designated as a breakthrough therapy for advanced cervical cancer. The therapy is being developed by Iovance Biotherapeutics. LN-145 is an experimental autologous TIL immunotherapy that might be used alone or in conjunction with other treatments.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the cervical cancer market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the cervical cancer market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current cervical cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the cervical cancer market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the cervical cancer market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the cervical cancer market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of cervical cancer across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of cervical cancer by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of cervical cancer by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with cervical cancer across the seven major markets?
• What is the size of the cervical cancer patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of cervical cancer?
• What will be the growth rate of patients across the seven major markets?
   

Cervical Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for cervical cancer drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cervical cancer market?
• What are the key regulatory events related to the cervical cancer market?
• What is the structure of clinical trial landscape by status related to the cervical cancer market?
• What is the structure of clinical trial landscape by phase related to the cervical cancer market?
• What is the structure of clinical trial landscape by route of administration related to the cervical cancer market?